Dear guests, investors and friends:
Hello everyone! Welcome to the online roadshow promotion activity of Chengdu Shengnuo Biotechnology Co., Ltd. for its IPO and listing on the Science and Technology Innovation Board.
Here, on behalf of the board of directors and all employees of Shengnuo Biotechnology, I would like to express our heartfelt thanks to investors and friends from all walks of life who have cared about and supported Shengnuo Biotechnology for a long time! I hope that through this online roadshow, everyone will have a more comprehensive, full and objective understanding of Shengnuo Biology.
Shengnuo Biotechnology is a high-tech enterprise with core peptide synthesis and modification technologies, with advanced and efficient peptide drug technology research and development and large-scale production capabilities.
Relying on the core technology advantages of peptide synthesis and modification,Shengnuo Biotechnology has gained high popularity and recognition in the field of peptide drug R&D and production. It has successively provided new drug R&D companies and scientific research institutions such as Suzhou Paige Biotech, Biotech Biotech, and Bajiayi. More than 30 projects of pharmaceutical research and customized production services have been provided, of which one innovative peptide drug has been approved and entered the commercialization stage, and another seven innovative peptide drugs have entered the clinical trial stage.
In the future, the company will seize the rapid growth of the peptide generic drug market, continue to deepen the peptide drug market, continue to improve process technology, research and development strength, marketing management, channel construction and comprehensive management capabilities, and improve overall competitiveness and profitability. The development trend of the global pharmaceutical industry is to focus on peptide API products, strengthen pharmaceutical research services for peptide innovative drugs, and customized production services for peptide products, actively integrate into the domestic and foreign pharmaceutical industry chain, extend the development of more peptide preparation varieties, and further increase The promotion strength and promotion management level of large preparations. At the same time, the company will actively deploy the peptide innovative drug business field through cooperative research and development, and consolidate the company’s competitive position in the industry.
The issuance and listing of Shengnuo Biotechnology stock is a milestone for the company. It is the successful implementation of another major strategic decision of the company, which will certainly promote the company’s leapfrog development again!
I sincerely hope that through today’s online communication activities, investors who have been following and supporting us will have a better understanding and recognition of Sino Biotech. We firmly believe that the high trust and strong support of investors will be an important guarantee for the successful issuance of Shengnuo Biotechnology.
Finally, I would like to thank investors, friends and all walks of life for their concern for Shengnuo Biological. We will definitely work hard to repay investors and society with excellent performance. thank you all!